BioCentury
ARTICLE | Finance

Ironed Out

February 8, 2010 8:00 AM UTC

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) didn't get the $1.2 billion pre-money and $1.4 billion post-money valuation it had hoped for, nor did it raise the $250 million it would have at the mid-point of its range.

The question in the after-market is whether there are any take home messages...